CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.16B, above the global median of $1.18B
- FinancialsAltman Z-Score 12.16: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
3.00TKRW2.16B · vs all stocks (USD)
Revenue (TTM)
98.78BKRW71.30M · vs all stocks (USD)
Profit Margin
-180.94%vs Biotechnology peers
Beta
0.4990xvs all stocks
52-Week Change
-47.41%vs all stocks
Market Capitalization
3.00TKRW2.16B · vs all stocks (USD)
Enterprise Value
2.73TKRW1.97B · vs all stocks (USD)
Price to Sales (TTM)
30.32xvs Biotechnology peers
Price to Book (MRQ)
6.86xvs Biotechnology peers
Enterprise to Revenue
27.59xvs Biotechnology peers
Enterprise to EBITDA
-13.70xvs Biotechnology peers
Gross Margin
57.18%vs Biotechnology peers
Profit Margin
-180.94%vs Biotechnology peers
Operating Margin
-1300.88%vs Biotechnology peers
Return on Assets (TTM)
-19.81%vs Biotechnology peers
Return on Equity (TTM)
-36.55%vs Biotechnology peers
Revenue (TTM)
98.78BKRW71.30M · vs all stocks (USD)
Revenue per Share (TTM)
2.70KKRWUpdated Sep 20, 2026Quarterly Revenue Growth
-83.00%vs Biotechnology peers
Gross Profit (TTM)
86.55BKRW62.47M · vs all stocks (USD)
EBITDA (TTM)
-198.89BKRW-143.56M · vs all stocks (USD)
Net Income (TTM)
-178.73BKRW-129.01M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-83.04%vs Biotechnology peers
Operating Cash Flow (TTM)
-191.62BKRW-138.31M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-144.32BKRW-104.17M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
33.51BKRWFY2025 · Dec 31, 2025Revenue
141.55BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
15.56BKRWFY2025 · Dec 31, 2025Gross Profit
126.00BKRWFY2025 · Dec 31, 2025Operating Income
-106.49BKRW-76.86M · vs all stocks (USD)
Pre-tax Income
-93.89BKRWFY2025 · Dec 31, 2025Income Tax Expense
-2.34BKRWFY2025 · Dec 31, 2025Net Income
-91.55BKRWFY2025 · Dec 31, 2025EBIT
-93.01BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-81.89BKRWFY2025 · Dec 31, 2025Research & Development
216.91BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
6.32BKRWFY2025 · Dec 31, 2025Other Operating Expenses
-850.54MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
18.38BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
883.19MKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
-91.55BKRWFY2025 · Dec 31, 2025Minority Interests (P&L)
17.27BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-137.23BKRWFY2025 · Dec 31, 2025Free Cash Flow
-140.28BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
98.65BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-91.55BKRWFY2025 · Dec 31, 2025Stock-based Compensation
3.91BKRWFY2025 · Dec 31, 2025Other Non-cash Items
-17.42BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
12.83BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-44.99BKRWFY2025 · Dec 31, 2025Capital Expenditures
-3.05BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-2.99BKRWFY2025 · Dec 31, 2025Net Acquisitions
9.15BKRWFY2025 · Dec 31, 2025Purchase of Investments
-363.25BKRWFY2025 · Dec 31, 2025Sale of Investments
454.28BKRWFY2025 · Dec 31, 2025Other Investing Activity
-10.00KRWFY2025 · Dec 31, 2025Net Investing Cash Flow
97.13BKRWFY2025 · Dec 31, 2025Common Stock Repurchase
-7.00BKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
242.70MKRWFY2025 · Dec 31, 2025Shares Outstanding
36.44MSharesUpdated Sep 20, 2026Float Shares
25.38MSharesUpdated Sep 20, 2026% Held by Insiders
29.24%vs all stocks
% Held by Institutions
14.05%vs all stocks
Total Cash (MRQ)
383.86BKRW277.07M · vs all stocks (USD)
Total Cash per Share (MRQ)
10.42KKRWUpdated Sep 20, 2026Total Debt (MRQ)
2.59BKRW1.87M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0059xvs Biotechnology peers
Current Ratio (MRQ)
9.37xvs Biotechnology peers
Book Value per Share (MRQ)
11.98KKRWUpdated Sep 20, 2026Total Assets
701.81BKRW506.57M · vs all stocks (USD)
Total Current Assets
521.44BKRWFY2025 · Dec 31, 2025Total Liabilities
160.69BKRWFY2025 · Dec 31, 2025Total Non-current Assets
180.37BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
99.60BKRWFY2025 · Dec 31, 2025Total Current Liabilities
61.09BKRWFY2025 · Dec 31, 2025Cash
654.46MKRWFY2025 · Dec 31, 2025Cash Equivalents
98.00BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
98.65BKRWFY2025 · Dec 31, 2025Other Short-term Investments
375.90BKRWFY2025 · Dec 31, 2025Accounts Receivable
11.76BKRWFY2025 · Dec 31, 2025Inventory
110.04MKRWFY2025 · Dec 31, 2025Accounts Payable
7.43BKRWFY2025 · Dec 31, 2025Short-term Debt
1.06BKRWFY2025 · Dec 31, 2025Other Current Liabilities
124.23MKRWFY2025 · Dec 31, 2025Long-term Debt
1.69BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
350.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
18.31BKRWFY2025 · Dec 31, 2025Retained Earnings
211.81BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
541.12BKRW390.58M · vs all stocks (USD)
Treasury Stock
13.94BKRWFY2025 · Dec 31, 202552-Week Low
76.90KKRWUpdated Sep 20, 202652-Week High
225.00KKRWUpdated Sep 20, 202652-Week Change
-47.41%vs all stocks
Beta
0.4990xvs all stocks
50-Day MA
99.80KKRWUpdated Sep 20, 2026200-Day MA
156.34KKRWUpdated Sep 20, 2026Avg 10-Day Volume
210.57KSharesUpdated Sep 20, 2026Avg 30-Day Volume
242.33KSharesUpdated Sep 20, 2026Diluted EPS (TTM)
-2.04KKRWUpdated Sep 20, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 30.32Revenue Growth YoY: -0.83
High gross margins eroded by operating costsNotable
Gross Margin: 0.57Profit Margin: -1.81
Financial Health
Altman Z-Score 12.16: safe zoneNotable
Altman Z-Score: 12.16
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.16B, above the global median of $1.18BNotable
Market cap (USD): 2,162,029,804.354Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Fujian Cosunter Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aurinia Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Verano Holdings Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
BioCryst Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Granules India Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Bausch Health Companies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ocular Therapeutix Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangzhong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Prestige Consumer Healthcare Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Ocwen Financial Corp
1 interpretationIndustry-Benchmarked ROA and Margin Elevated
ALTEOGEN Inc.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated
Sylvamo Corporation
1 interpretationIndustry-Benchmarked ROA and Margin Elevated